Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840902 | 0.85 | LMNA (0.52) | PARP14ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3378287 | 0.84 | AKT1 (0.61) | PARP14PDE3BPDE3AALDH1A1L3MBTL1 | |
| SCHEMBL20320868 | 0.79 | TPH1 (0.45) | PIK3CDPIK3CBALDH1A1L3MBTL1KDM4E | |
| SCHEMBL20424755 | 0.78 | TP53 (0.54) | PIK3CDPIK3CBALDH1A1KDM4EMEN1 | |
| SCHEMBL12212362 | 0.78 | ALDH1A1 (0.54) | ALDH1A1KDM4EMEN1POLBKMT2A | |
| SCHEMBL8320097 | 0.78 | HDAC1 (0.50) | PIK3CDPIK3CBALDH1A1L3MBTL1KDM4E | |
| SCHEMBL5515307 | 0.77 | AURKA (0.45) | PIK3CDPIK3CBCYP3A4 | |
| SCHEMBL3845055 | 0.77 | PDGFRB (0.44) | HTR2B | |
| SCHEMBL3378290 | 0.76 | AKT1 (0.62) | PDE3BPDE3APIK3CDPIK3CBALDH1A1 | |
| SCHEMBL6784582 | 0.76 | SIRT2 (0.43) | PARP14PDE3BPDE3APIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313734-B1 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| US-7138409-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050137188-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| US-6759417-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS; SUCH AS 7-AMINO-6-(1H-BENZIMIDAZOL-2-YL)-3,4-DIHYDRO-5H-IMIDAZO(4,5-B)PYRIDIN-5-ONE | CHIRON CORPORATION | 2004-07-06 | — | — | US | disclosed |
| US-6756383-B2 | SUCH AS 3-(2-(METHOXYCARBONYL)ACETYLAMINO)PYRIDINE-4-CARBOXYLIC ACID FOR TREATMENT OF DISEASES CHARACTERIZED BY ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES; ENZYME INHIBITORS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20040002518-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2004-01-01 | — | — | US | disclosed |
| EP-1313734-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
| WO-2002018383-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | PARP14 4267/4885PDE3B 1112/4885PDE3A 1026/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | PARP14 3929/4885PDE3B 1211/4885PDE3A 1342/4885 |
| US-20050137188-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | PARP14 3929/4885PDE3B 1211/4885PDE3A 1342/4885 |
| US-20040002518-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | PARP14 4267/4885PDE3B 1112/4885PDE3A 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.